GlassScriptPhysician profile
David C Boorman
NPI 1659344471
$2,809.98
in general payments reported to CMS, 2019-2025
23 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $310 · 2021: $754 · 2022: $706 · 2023: $310 · 2024: $246 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $687.71 | 2019-2025 | |
| Amgen INC. | $385.99 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $344.32 | 2019-2023 | Xarelto |
| Pfizer INC. | $217.63 | 2019-2022 | |
| Abiomed | $186.77 | 2020-2021 | |
| Medtronic, INC. | $181.33 | 2021-2025 | Symplicity G3, Micra |
| Boston Scientific Corporation | $118.15 | 2021-2025 | Watchman Flx, General - Pain Management, Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $96.76 | 2019-2023 | Uptravi, Opsumit |
| Abbott Laboratories | $89.39 | 2019-2023 | Assurity |
| Medtronic Vascular, INC. | $86.05 | 2019 | |
| Chiesi USA, INC. | $62.65 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.57 | 2021-2022 | |
| Amarin Pharma, INC. | $52.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $37.68 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $34.46 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $24.81 | 2019-2022 | |
| Daiichi Sankyo INC. | $17.83 | 2024 | Injectafer |
| Cardinal Health 200 LLC | $16.77 | 2021 | |
| Merck Sharp & Dohme LLC | $16.06 | 2022 | |
| Genzyme Corporation | $15.82 | 2019 | |
| Asahi Intecc USA, INC. | $14.29 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Boorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.